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Abstract. – OBJECTIVE: Ulcerative Colitis
(UC) is a chronic inflammatory disease of the
colon of unknown etiology. Several clinical in-
dexes have been proposed for UC disease ac-
tivity evaluation, but none have been properly
validated. Moreover, the reference parameter
for the scores and their prognostic value is not
clear. Mucosal healing has been recently pro-
posed as an important end-point. Aim of the
present study was to evaluate the correlation of
four clinical indexes with objective diagnostic
tools for UC evaluation, the discriminative abili-
ty in identifying patients with endoscopic mu-
cosal healing, and to analyze the possible prog-
nostic indication for disease course in 1 year of
follow-up.
PATIENTS AND METHODS:We analyzed data
of 75 patients recorded in regular follow-up vis-
it in IBD clinic at S. Andrea Hospital, Rome, be-
tween 2007-2011. We recorded clinical data and
lab tests at the time of the visit, and endoscop-
ic/histological reports performed within 1
month. Clinical indexes (Seo’ activity index,
Simple Clinical Colitis Activity Index, partial
Mayo score and Endoscopic-Clinical Correla-
tion Index) were calculated and correlation to
endoscopic and histologic activity, and to C-re-
active protein increment, was assessed by
mean of Spearman’s rank correlation. Discrimi-
native ability of the indexes for patients with
and without endoscopic mucosal healing was
tested by calculation of area under ROC curve
(AUC). Patients with low and high clinical
scores were compared for number of flares and
increment of therapy during 1 year of follow-up.
RESULTS: Clinical indexes had a good correla-
tion with endoscopic activity (mean r = 0.73 ±
0.06), a fair correlation with CRP-increment
(mean r = 0.55 ± 0.01) and a poor one with histo-
logic activity (mean r = 0.35 ± 0.01). The discrimi-
natory ability of the indexes for endoscopic mu-
cosal healing was good for all the indexes (mean
AUC = 0.87 ± 0.05). Patients with high clinical
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score had more flares and required more fre-
quently increase of therapy at 1 year of follow up
compared with patients with low score.
CONCLUSIONS: Clinical indexes have a good
correlation with endoscopic activity and can
discriminate patients with and without mucosal
healing. Patients with low and high score have
different risk of disease flare and of need to in-
crease therapy at 1 year. Clinical indexes may
represent a useful tool for disease assessment
in clinical practice in UC outpatients with mild-
moderate disease.
Key Words:
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Introduction
Ulcerative Colitis (UC) is a chronic inflamma-
tory bowel disease (IBD), involving the colon, of
unknown etiology and immune pathogenesis,
clinically characterized by the alternation of peri-
ods of remission and flares of the disease1. De-
spite constant progress in the basic and clinical
research, UC still presents several challenges for
the physician. One crucial issue in the clinical
management of UC patients is the evaluation of
the disease activity. In fact, UC may be charac-
terized by different grade of bowel inflammation,
in terms of severity and extension, that in turn
may lead to alteration of macro- and microscopic
pattern of colonic mucosa, as well as presence
and severity of clinical symptoms (i.e. diarrhea,
bloody stools, abdominal pain, fever). Since clin-
ical symptoms, lab tests, endoscopic appearance
and histological examination may be discordant,
it is not yet clear which parameter should be the
reference for the evaluation of the real activity of
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the disease2. In recent years, the endoscopic ‘mu-
cosal healing’, has been more and more indicated
as an important end-point for the management of
UC patients, for its association with a better short
and long-term prognosis3, although several as-
pects of that issue are far from being clarified4.
Besides, endoscopy should represents the ‘gold
standard’ for disease activity evaluation in UC,
for it provides a direct evaluation of the colon,
which is the target organ of the disease. Unfortu-
nately, endoscopic examination is costly, not eas-
ily accepted by patients and not available in short
time in many centers, so that routinely repetition
of colonoscopy is not feasible nor appropriate.
In order to help physicians in clinical practice
and to simplify and objectify the evaluation of
UC activity in clinical trials, several clinical in-
dexes have been developed5. The main limitation
of all those indexes is the lack of an adequate
validation in large and independent cohorts of
patients. Moreover, the reference parameter
whom the numeric score is referred to is often
not completely clear, so that the prognostic utility
of such indexes remains to be clarified. Nonethe-
less, a clinical score strongly correlated to en-
doscopy and predictable of the disease course
would be useful for several purposes. First, it
would provide an easy useful tool for patients
and physicians to evaluate and monitor UC activ-
ity even in not referral centers. This would be of
particular relevance especially for the manage-
ment of mild-moderate UC outpatients, in which
the clinical score would help in discriminating
patients who need further investigation (i.e.
colonoscopy), shorter follow-up visits, and/or in-
tensification of the current treatment, and pa-
tients in which regular follow-up is sufficient, in
order to optimize resources with evident eco-
nomic and clinical benefits. Second, it would
provide an objective and reproducible tool to
evaluate patients in clinical trials, both for base-
line evaluation and for the response to therapy.
Aim of our study was to evaluate, in a cohort
of UC patients in our hospital, the correlation of
four clinical indexes (Seo’s clinical index, Walm-
sley’s Simple Clinical Colitis Activity Index –
SCCAI, Endoscopic Clinical Correlation Index –
ECCI, and partial Mayo score), with objective
parameters of evaluation of disease activity (en-
doscopic examination, histology and C-reactive
protein – CRP), with particular regard to the ac-
curacy in identifying patients with endoscopic
mucosal healing. Moreover, we intended to ex-
plore the possible prognostic indications of the
clinical scores evaluating the disease course of
the patients (disease flare and therapeutic incre-
ment) at 1 year of follow-up.
Patients and Methods
Patients
Clinical charts of patients of the IBD Outpa-
tients Clinic (Digestive and Liver Disease Unit)
at S. Andrea Hospital in Rome, Italy, are collect-
ed in an electronic database. We analyzed pa-
tients with an established diagnosis of UC (ob-
tained by clinical, endoscopic and histologic
compatible with UC) who performed a regular
follow-up visit from 2007 and 2011. Inclusion
criteria were: patients who performed a regular
scheduled visit and who had clinical examina-
tion, laboratory tests and a complete colonoscopy
performed within an interval of time no longer
than 1 month, who had a complete record of the
clinical and laboratoristic parameters necessary
for the calculation of the clinical scores, and who
have a documented 1-year follow-up from the
time of the visit. In particular, the clinical fea-
tures necessary for the calculation of the scores
were the following: general condition evaluation,
number of bowel movements per day, number of
nocturnal bowel movement, number of evacua-
tion with blood and quantity of the blood in
stools, presence of urgency, extra-intestinal dis-
ease manifestations and fever. The lab tests re-
quired were the following complete blood count,
erythrocytes sedimentation rate (ESR), serum al-
bumin level and C-reactive protein (CRP). Exclu-
sion criteria were: patients with an uncertain di-
agnosis of UC, patients at their first visit or with
a severe flare of disease, patients who did not
have a documented report of any of the parame-
ters necessary for the calculation of the clinical
scores (i.e. clinical examination and lab tests), or
with an incomplete endoscopic examination and
patients without 1-year of documented follow-
up. Finally, 75 patients fulfilled the inclusion cri-
teria for the study. In all but 8 patients (11%),
clinical examination and lab tests were done be-
fore colonoscopy.
Clinical Indexes Evaluation
We utilized four clinical index (i.e. SEO activ-
ity index, Walmsley’s SCCAI, partial Mayo
score, and ECCI) among the most commonly
used in the literature for UC patients, and we cal-
culated them according to the original articles6-9.
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Results
The characteristics of the 75 patients finally
included in the study are summarized in Table I.
All the clinical indexes tested displayed a
good correlation with endoscopic activity (Mayo:
r = 0.77, SCCAI: r = 0.75, ECCI: r = 0.77, SEO:
r = 0.64; p < 0.0001) (Figure 1 A). Correlation of
the indexes with the histologic score was poor
(Mayo: r = 0.35, SCCAI: r = 0.33, ECCI: r =
0.36, SEO: r = 0.36; p < 0.005) (Figure 1 B).
Considering the CRP increment, the correlation
with the indexes was fair (Mayo: r = 0.54, SC-
CAI: r = 0.55, ECCI: r = 0.55, SEO: r = 0.57; p <
0.0001) (Figure 1 C).
We then calculated the ability of the indexes to
discriminate patients with and without endoscop-
ic mucosal healing (Baron endoscopic score ≤1).
All the tested score displayed a very good dis-
criminative ability with a comparable area under
the ROC curve (AUC) (mean AUC = 0.87±0.05)
(Figure 2). The AUC values, together with sensi-
tivity and specificity of every single score, are re-
ported in Table II.
According to the cut-off levels for “severe” dis-
ease of every single index already described in lit-
For every index it was calculated the correlation
with the endoscopic activity, the histologic activi-
ty and the increment of CRP. The endoscopic ac-
tivity was evaluated by a modified Baron score,
composed by the sum of the single score of the
five colonic segments (rectum, sigma, descend-
ing, transverse and ascending colon/caecum)10,11.
The histologic activity was evaluated by Sand-
born’s score, with the total score resulting from
the sum of every single colonic segment12. Baron
and Sandborn’s scores, calculated from the endo-
scopic and histological reports, and clinical in-
dexes were independently calculated by different
operators in a blind fashion. The CRP was ex-
pressed by a relative ratio to the highest normal
value. Thus, the diagnostic capacity of every sin-
gle clinical score in discriminating patients with
endoscopic mucosal healing (defined by a Baron
endoscopic score ≤ 1) was evaluated. Finally, the
capacity of the indexes in predicting the necessi-
ty of an increase of therapy and the occurrence of
flare, in a period of 1 year of follow up from the
initial evaluation, was evaluated. The increment
of therapy was defined by increment of dose of
current therapies and/or addition of new drugs.
The flare was generally defined by the onset or
exacerbation of symptoms (i.e. abdominal pain,
increased bowel movements, blood in stools, ur-
gency) that required the prompt access to a med-
ical consultation (general practitioner, specialist
or emergency room).
Statistical Analysis
The correlation between clinical indexes and
endoscopic score, histologic score and CRP in-
crement was evaluated by Spearman’s rank cor-
relation. Discriminative ability of every single in-
dex for mucosal healing was calculated by quan-
tification of the area under receiver operator
characteristic (ROC) curve and compared to oth-
er indexes’ ROC curve. Sensitivity and specifici-
ty of every clinical index in detecting endoscopic
mucosal healing were calculated. Finally, we
identified two groups of patients (low and high
score), according to the cut-off value already de-
scribed in literature for every clinical index. The
number of patients, in the two groups, who need-
ed an increase of therapy and who experienced a
flare of disease was recorded and compared by
chi-squared test. Odds ratios (OR) with 95% con-
fidence intervals (CI) were calculated. A value of
p < 0.05 was considered statistically significant.
Med Calc statistical software version 12.5 was
used for statistical calculation.
Characteristics N (%)
Age (y) 49.7 ± 17.8*
Gender (M) 38 (51%)
Disease Localization:
• Proctitis 8 (11%)
• Left colitis 21 (28%)
• Extensive colitis 46 (61%)
Disease activity (clinical indexes):
• Mayo 3.7 ± 3*
• SCCAI 4.5 ± 3.3*
• ECCI 64.4 ± 55.5*
• SEO 160.9 ± 50.7*
Disease duration (years) 8.62 (1-32)**
Therapy:
• Oral salicylates 38 (50.7%)
• Topical salicylates 6 (8%)
• Oral + topical salicylates 23 (30.7%)
• Corticosteroids 0 (0%)
• Tiopurines 1 (1.3%)
• Biologics 1 (1.3%)
• None 6 (8%)
Endoscopic mucosal healing 17 (23%)
Flare at 1 yr 27 (36%)
Increase of therapy at 1 yr 51 (68%)
Table I. Characteristics of the 75 patients included in the
study.
*
= mean ± SD, ** = years range
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Figure 1. Correlation between clinical indexes and endoscopic score (A), histologic score (B) and CRP increment (C). Spear-
man’s correlation of the indexes was very good with endoscopic score (mean r = 0.73 ± 0.06; p < 0.0001) (A), while it was not
satisfactory with histologic score (mean r = 0.35 ± 0.01; p < 0.005) (B), and fairly good with the CRP increment (mean r =
0.55 ± 0.01; p < 0.0001) (C). Regression line in represented in A and B, but not in C, since CRP has been evaluated as ratio to
the normal value and its increment is not linear.
3678
C. Pagnini, F. Menasci, S. Festa, G. Rizzatti, V.D. Corleto, M.M. Delle Fave, et al.
Score AUC ± SE 95% CI p Sensitivity Specificity
ECCI 0.89 ± 0.04 0.80 – 0.95 <0.0001 86.2 82.4
Partial Mayo 0.86 ± 0.05 0.76 – 0.93 <0.0001 81 82.4
SEO 0.84 ± 0.05 0.74 – 0.92 <0.0001 79.3 82.4
SCCAI 0.89 ± 0.04 0.79 – 0.95 <0.0001 87.9 76.5
Table II.Accuracy of discrimination of clinical scores for endoscopic mucosal healing.
AUC =Area Under ROC Curve, CI = confidence interval.
Discussion
In the present work, we tested four clinical in-
dexes in UC patients. We first evaluated the cor-
relation with recognized objective parameter of
disease assessment, and in particular with endo-
scopic ‘mucosal healing’, and then we explore
the possible indication for the practical manage-
ment of the patients, by means of the assessment
of the relation with the scores and the disease
course in one year of follow-up. Since to date
there is not a single index universally accepted
and validated, different clinical scores are vari-
ably used in literature, and their utilization in dai-
ly clinical practice is not encouraged by specific
designed studies. We chose four simple clinical
erature (partial Mayo ≥ 2, SCCAI ≥ 3, ECCI ≥
55, SEO ≥ 120 points), we identified two groups
of patients (low and high-score group). Thus,
number of patients who had disease flare and who
required therapy modifications, in the two groups
of patients, was compared. Considering flares, pa-
tients with a low score had reduced relapse of dis-
ease at 1 year comparing to patients with high
score (Figure 3 A). In particular, the difference
was statistically significant for ECCI [9/38 (30%
of patients) vs. 18/37 (49%) of flares in low- and
high-score group, respectively, p < 0.05]. Consid-
ering number of patients who required increment
of therapy at 1 year, all the scores displayed a
consistent difference between low and high score
groups [ECCI: 21/38 (55%) vs. 30/37 (81%), p <
0.05; SEO: 12/26 (46%) vs. 39/49 (79%), p <
0.01; SCCAI: 13/25 (52%) vs. 38/50 (76%), p =
0.07; Mayo: 9/20 (45%) vs. 42/55 (76%), p <
0.05] (Figure 3B). For all the indexes, the group
of patients with high score had higher risk of flare
and of increase of therapy at 1 year (Table II).
Figure 2. Comparison of ROC curves of clinical indexes
for discrimination of endoscopic ‘mucosal healing’. All the
indexes displayed a good discriminative ability (mean AUC
= 0.87 ± 0.05).
Figure 3. Comparison of number of patients with flare of dis-
ease (A) and who required an increase of therapy (B), in high-
and low- score groups, at 1 year of follow-up. Patients with
high score experienced more flares and required more increase
of therapy comparing with patients with low clinical score.
3679
Application of clinical indexes in ulcerative colitis patients in regular follow-up visit
indexes among the most commonly used in the
literature, and we focused their utilization of UC
patients with mild disease in regular follow-up
visit. In this setting, clinical indexes may identify
a low-risk group of patients with a probable fa-
vorable course of disease, at least at 1 year, in
which aggressive follow-up and/or treatment is
unnecessary. On the other side, they may suggest
further diagnostic procedures and/or close re-
evaluation in patients with still mild disease but
with a high clinical score, suggestive of active
disease. Moreover, a simple and not time-con-
suming score may help to monitor patients’ re-
sponse to therapy in trials and clinical practice.
Few studies directly compared different scores
in the same set of patients. Turner et al13 prospec-
tively evaluated nine clinical indexes in 86 UC
patients. Validity of the scores was tested by cor-
relational analysis with different parameters (i.e.
colonoscopy score, physician and patient global
assessment, Mayo score and lab tests). In accord
with the present study, the clinical indexes dis-
played very good correlation with the endoscopic
score and good correlation with CRP level. The
authors conclude that SCCAI and the pediatric
ulcerative colitis activity index (PUCAI) showed
the better results among the tested index and may
be of help in clinical practice. Hirai et al14 evalu-
ated the performance of both clinical and endo-
scopic index in patients prior to treatment, at 2, 4
and 8 weeks of treatment. The authors observed a
significant decrease in clinical and endoscopic
scores after treatment and a good correlation
among clinical indexes and between those and
the endoscopic scores. Interestingly, the correla-
tion was higher after treatment comparing with
the baseline, suggesting that the clinical scores
are related to the endoscopic activity in particular
in mild disease, such as in the setting of patients
of the present study (patients with mild disease in
regular follow-up).
One major problem of clinical scores is the
lack of a single reference parameter for the dis-
ease assessment. In the present work, we evaluat-
ed correlation between clinical indexes and ob-
jective diagnostic tools of particular relevance for
UC patients evaluation and follow-up. Indeed,
the clinical scores displayed a good correlation
with endoscopy appearance, and to a lesser de-
gree, to CRP increment. As already mentioned,
endoscopy should represent the ‘gold standard’
for disease evaluation, for the direct observation
of the mucosa. Its importance have even more
emphasized by recent investigations underlining
the relevance and the prognostic value of ‘mu-
cosal healing’, proposed as fundamental thera-
peutical end-point15,16. Since endoscopic appear-
ance and clinical symptoms are sometimes diver-
gent, and considering the possible confounding
role of the sole symptoms in the management of
UC patients17, the good correlation of the scores
to the endoscopy is encouraging. The present
study evaluates for the first time the accuracy of
clinical indexes for the identification of patients
with ‘mucosal healing’. Considering the prog-
nostic value of a healed mucosa in UC patients,
the good accuracy of the indexes for mucosal
healing may confirm their potential role in dis-
criminating outpatients with higher or lower risk
of unfavorable outcome.
We used for a comparison with lab activity of
disease the CRP level increment, for its large use
and availability in many centers. A novel bio-
marker of disease, namely fecal calprotectin,
have been proven to strongly correlate with in-
flammatory activity18, and testing the correlation
of the scores with that parameter would be inter-
esting. Some authors19,20 have suggested a possi-
ble prognostic role for histological assessment,
beside the macroscopic appearance, and the cor-
relation with macroscopic and microscopic activ-
ity has been debated21. Bessissow et al22 reported
Flare Increased therapy
Score OR 95%CI OR 95%CI
Partial Mayo 2 0.64-6.3 3.95 1.34-11.61
Seo 2.5 0.85-7.31 4.55 1.61-12.85
SCCAI 1.71 0.61-4.85 2.92 1.06-8.09
ECCI 3.05 1.14-8.19 3.47 1.22-9.84
Table III. Increase of risk of flare and of increase of therapy in high vs. low score patients.
AUC =Area Under ROC Curve, CI = confidence interval.
a higher flare occurrence in patients with endo-
scopic macroscopic remission and histologic ac-
tivity (in particular the presence of basal plasma-
cytosis) comparing with patients with complete
macro- and microscopic remission. To date, rou-
tinely evaluation of bioptic samples in UC pa-
tients is not suggested by guidelines nor com-
monly used in clinical practice, and further re-
searches are needed to better investigate the role
of histologic activity in the management of UC
patients. In our set of patients, histology poorly
correlated with the clinical scores, despite a fair
correlation with the endoscopic index (r = 0.55, p
< 0.0001). Nonetheless, that result has to be in-
terpreted with caution, considering that the histo-
logic score was evaluated from the reports and
not expressly calculated by the anatomopatholo-
gist.
Indeed, the prognostic value of the clinical
scores have been scarcely investigated. However,
we intended to explore that issue by evaluation of
disease course after 1 year from the first clinical
evaluation, in order to test the possible predictive
suggestion of each score on the course of the dis-
ease. It is to note that we defined flare of disease
as any general onset or exacerbation of symp-
toms suggestive of bowel inflammation, and that
we consider any increment of the therapy that
have been prescribed, regardless of a significant
worsening of the underlying clinical condition.
Consequently, in our retrospective casistic of pa-
tients in a regular follow-up visit, the clinical
scores identified particularly patients with con-
sistent favorable course of disease, since about
75% of patients with low score did not recorded
any flare of disease and about 50% did not modi-
fy their therapy at 1 year of follow-up. In order to
test possible prognostic value of clinical scores,
specific prospectic studies in large setting of pa-
tients are needed.
The main limitation of the present work is de-
termined by the retrospective analysis of the da-
ta, which would have influenced the results in
several ways. First, although we include only
patients with a complete set of clinical, lab and
endoscopic data available, some clinical data
may have been misinterpreted, and that would
have altered the performance of the scores that
require a more precise clinical assessment (i.e.
Mayo and SCCAI). In fact, the assessment of
patients’ general condition strictly depends on a
face-to-face visit, with direct interview and
physical examination. This could in part explain
the relative less striking performance of Mayo
and SCCAI, and the good results of ECCI, com-
paring with previous comparative studies13. In
fact, since ECCI include only objective parame-
ters and not the general assessment of the pa-
tients, it may have minor problems in the retro-
spective calculation, in contrast to what could
have happened for Mayo and SCCAI. Another
explanation for the good results of the ECCI
score is the fact that this is the only index ex-
pressly developed on endoscopic activity9.
Nonetheless, the design of the study and the rel-
ative low number of patients do not allow an ac-
curate comparison between the scores.
A further potential flaw is the fact that the en-
doscopic and histologic score have been retro-
spectively calculated. We used the modified
Baron score since it is widely used in literature
and it is simple and easily calculable even from
the colonoscopy reports. Clinical trials usually
indicate as endoscopic “mucosal healing” an en-
doscopic Mayo score ≤ 1. Similarly, in the pre-
sent paper, we defined ‘mucosal healing’ a
Baron score ≤ 1. Histological scores are less
used, but several reports indicate that histology
evaluation may add important information for
the clinical management to the sole macroscopic
observation23, so that some numeric scores have
been described20. Among the latter, we used the
Sandborn’s score, for it represents a simple and
useful tool for histologic assessment12. For the
relatively low number of patients, we did not
stratify patients according to the kind of therapy
followed at the time of the visit, so that we can-
not exclude variation in clinical score calcula-
tion and in the flare rate for the different thera-
pies. Therefore, the results of the present study
need to be taken with caution and further con-
firmed in large prospective studies. Nonetheless,
the present report confirms the usefulness of
clinical score for UC activity evaluation, for the
good correlation with endoscopy. For that rea-
son, utilization of clinical indexes may be of
help in the practical management of UC patients,
in particular in outpatients with mild-moderate
disease, with potential implication for resources
optimization.
Conclusions
Clinical indexes may represent a useful tool in
the daily practice for UC patients’ management,
for the good correlation with endoscopic activity
and the accuracy in identifying patients with mu-
3680
C. Pagnini, F. Menasci, S. Festa, G. Rizzatti, V.D. Corleto, M.M. Delle Fave, et al.
cosal healing. Prospective multicentric investiga-
tions in large sets of patients are necessary in or-
der to better examine the prognostic value of the
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